American Century Companies Boosts Stake in Edgewise Therapeutics

Investment firm increases holdings in biotech company focused on rare diseases

Published on Mar. 11, 2026

Got story updates? Submit your updates here. ›

American Century Companies Inc. has increased its stake in Edgewise Therapeutics, Inc. (NASDAQ:EWTX) by 39.9% in the third quarter, according to a recent SEC filing. The institutional investor now owns 1,095,473 shares of the company's stock, worth approximately $17.8 million.

Why it matters

Edgewise Therapeutics is a clinical-stage biopharmaceutical company developing treatments for rare kidney and neuromuscular diseases. The increased investment by American Century Companies suggests confidence in the company's pipeline and future prospects.

The details

American Century Companies acquired an additional 312,307 shares of Edgewise Therapeutics in the third quarter, bringing its total stake to 1,095,473 shares, or about 1.03% of the company. Edgewise Therapeutics is focused on developing small-molecule therapies for conditions like focal segmental glomerulosclerosis (FSGS) and other proteinuric kidney diseases.

  • American Century Companies increased its stake in Edgewise Therapeutics during the 3rd quarter of 2026.

The players

American Century Companies Inc.

An investment management firm based in Kansas City, Missouri that manages over $200 billion in assets.

Edgewise Therapeutics, Inc.

A clinical-stage biopharmaceutical company headquartered in Cambridge, Massachusetts that is developing treatments for rare kidney and neuromuscular diseases.

Got photos? Submit your photos here. ›

The takeaway

The increased investment by American Century Companies in Edgewise Therapeutics suggests confidence in the biotech company's ability to develop successful treatments for rare diseases, which could provide hope for patients and their families.